|
|
RAS blockade in the real world: Clinical lessons from recent trials
|
|
|
|
Age-adjusted Percentage of U.S. Adults who were Obese or who Had Diagnosed Diabetes
|
|
|
|
Absolute Numbers of Cases with Diabetes among Chinese Adults (>20yrs of Age) according to Urban or Rural Residence
|
|
|
|
Age-Specific Prevalence of Diabetes among Chinese Adults 20 Years of Age or Older
|
|
|
|
Prevalence of Diabetes and Prediabetes in Relation to Body Mass Index in the Chinese Population
|
|
|
|
Hazards of Prediabetes
|
|
|
|
Lifestyle Intervention in Prediabetes
|
|
|
|
Slide 8
|
|
|
|
Slide 9
|
|
|
|
Actos Now for Prevention of Diabetes (ACT NOW)
|
|
|
|
ACT NOW:
Time to Occurrence of Diabetes (Kaplan Meier)
|
|
|
|
Effects of Pioglitazone as compared with Placebo
|
|
|
|
Factors contributing to cardiometabolic risk
|
|
|
|
Goals for intensive multifactorial Management for CVD Prevention in Patients with Diabetes
|
|
|
|
Drug treatment: Stepwise and target driven (Steno 2 Study)
|
|
|
|
STENO 2: Changes in Risk factors during the follow-up of 8 years in the intensive versus conventionally treated type 2 diabetic patients
|
|
|
|
The cumulative incidence of the risk of death from any cause (the study’s primary end point) during the 13.3-year study period
|
|
|
|
New Evidence shows that a Legacy Effect („Metabolic Memory“) of Intensive Glucose Control is relevant for a significant Reduction of CVD Events & CVD Mortality after Long-term follow-up (10-18 years)
|
|
|
|
DCCT: Intensive therapy significantly reduces and maintains HbA1c
|
|
|
|
Cumulative Incidence of the first of any of the first Occurrence of Nonfatal Mycardial Infarction, Stroke, or Death from CVD
|
|
|
|
Clinical Characteristics and Effects of Intensive Glucose
Lowering on Primary Cardiovascular (CVD) Endpoint, Total Mortality, & CV Mortality in ACCORD, ADVANCE & VADT
|
|
|
|
Hypoglycemia Medical Assistance
|
|
|
|
Mortality in ACCORD (5 year-Data)
|
|
|
|
ACCORD: Adjusted cause of death in relation to treatment strategy and by occurence of hypoglycemia
|
|
|
|
CVD Mortality in ACCORD versus ADVANCE
|
|
|
|
The epidemiological and interventional relationships of cholesterol, blood pressure and HbA1c with cardiovascular disease
|
|
|
|
Adjusted Hazard Ratios for All-cause Mortality by HbA1c Deciles With Oral Combination & Insulin-based Therapies
|
|
|
|
Glycemic Control, Complications, and Death in Older Diabetic Patients
|
|
|
|
Mortality of Patients with Type 2 Diabetes in the Kaiser-Permanente Cohort in Relation to HbA1c (adjusted Hazard Ratios)
|
|
|
|
Any Complications or Death of Patients with Type 2 Diabetes in the Kaiser-Permanente Cohort in Relation to HbA1c (adjusted Hazard Ratios)
|
|
|
|
Is the ADA/EASD algorithm for the management of type 2 diabetes based on evidence or opinion? A critical analysis
|
|
|
|
ADA-EASD „Consensus“ : Expected HbA1c decrease (%) for well-validated and less validated core therapies
|
|
|
|
ADA and EASD: Decrease in HbA1c .... fact or fiction ?
|
|
|
|
Durability of Glycemic Control with Thiazlidinediones
|
|
|
|
No Durability of Glycemic Control with Sulfonylureas
|
|
The case for early management & prolonged glycemic control. prof schernthaner (PPTX 1.2MB)
Share this page with your colleagues and friends: